CClinicalTrials.gg
Status unknownNCT03061526Updated Mar 2, 2023

Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion

An observational study in Retinal Ischemia, sponsored by Technische Universität Dresden. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Technische Universität Dresden · Observational

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Retinal vessel occlusions might lead to ischemia of the inner retina, more severe so in artery occlusions. Intracellular edema may develop and decrease transparency of those layers, showing retinal edema. In spectral domain optical coherence tomography (SD-OCT) retinal reflectivity changes as a result of retinal edema. The investigators examine the reflectivity changes of different retinal layers between healthy eyes and eyes with retinal artery occlusion and ischemic or non-ischemic vein occlusions. Aim of the study is to evaluate whether those changes can be used to measure the level of ischemia in the inner retina.

Read the detailed description

Several studies tried to classify retinal ischemia due to retinal artery or vein occlusion into different grades. In some cases prognosis is dependent on grade of severity, especially in cases of retinal vein occlusion. State of the art to Diagnose the severity of retinal ischemia is lfuorescein angiography. However, this technique is invasive and might cause Problems like anaphylactic shock. Optical coherence tomography is a non-invasive technique, but up to now there is no standardized method to quantify the grade of severity of retinal ischemia in such conditions like retinal vessel occlusion. The study hope to find criteria by which such a classification can be constructed.

02

Conditions studied

  • Retinal Ischemia

Browse trials for

03

In context

Ischemia

2,058 studies on the registry are indexed under Ischemia; 347 are open to participants now.

This study's planned enrollment of 100 is below the median of 181 across 617 observational studies indexed under Ischemia.

Browse Ischemia studies →

Lead sponsor

Technische Universität Dresden is the lead sponsor of 237 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chart Review of patients treated b/o retinal vessel occlusion, who were examined with optical coherence tomography

Inclusion criteria

  • acute Retinal vessel occlusion on one eye
  • healthy contralateral eye
  • examined with spectral Domain optical coherence tomography

Exclusion criteria

Exclusion Criteria:

  • retinal occlusion older than 1 week
  • OCT Image not obtainable/missing
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Otheroptical coherence tomography

    measurement of reflectivity in different retinal layers based on optical coherence tomography findings

06

What researchers measure

Primary outcomes

  1. reflectivity

    optical density of different retinal layers

    Time frame: December 2017

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03061526
Lead sponsor
Technische Universität Dresden
Responsible party
Dr.med. Egbert Matthé (Principal Investigator, Technische Universität Dresden) — Principal investigator
First posted
Feb 23, 2017
Start date
May 1, 2017
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 2, 2023

Study contacts

Egbert Matthé, MD
Contact
egbert.matthe@uniklinikum-dresden.de
+493514583381
Olga Furashova
Contact
Egbert Matthé, MD
principal investigator · Technical University Dresden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion